The technology leverages immunotherapeutic IgE to develop treatment for cancer patients expressing the tumor-associated antigen PSA that is coupled with prostate cancer.
The anti-PSA monoclonal IgE demonstrated ability to selectively open the circulation improving the cytotoxic therapy ability in reaching cancers in addition to activating specific cellular immune responses against PSA in preclinical studies.
Quest CEO Dr. Madi Madiyalakan said, "Both IgG and IgE technologies are complementary and provide a novel approach for enhancing the effectiveness of chemotherapy while activating specific immunity to fight the cancer."
According to the deal, UCLA will receive upfront fee, milestone and royalty payments from Quest on future revenues.
The licensed technology has three pending patent applications.